Table.
Select clinical trials evaluating HIV-1 vaccine design strategies.
| Clinical trial No. | Immunogen | Estimated end date |
|---|---|---|
| NCT03220724 | CH505TF, week 53, week 78, week 100 DNA Mosaic-Tre |
2022 |
| NCT02256631 | VRC01 VRC01LS VRC07-523LS |
2021 |
| NCT03699241 | BG505 SOSIP.664 gp140 | 2020 |
| NCT03816137 | ConM SOSIP gp140 EDC ConM SOSIP gp140 ConS UFO gp140 EDC ConS UFO gp140 Mosaic SOSIPs gp140 |
2020 |
| NCT02716675 | VRC01 | 2020 |
| NCT02568215 | VRC01 | 2020 |
| NCT03547245 | eOD-GT8 60mer 20 μg + ASO1B/DPBS sucrose | 2020 |
| NCT02824536 | 3BNC117 10–1074 |
2018 |
| NCT02362217 | AdCh3NSmut1 MVA-NSmut CHAdV63.HIVconsv MVA.HIVconsv |
2017 |
| NCT02366013 | rcAd26.MOS1.HIV-Env | 2016 |
| NCT02315703 | Ad26.Mos.HIV MVA-Mosaic gp140 DP |
2016 |
| NCT02099994 | Ad35-GRIN MVA.HIVconsv pSG2.HIVconsv DNA Electroporated pSG2.HIVconsv |
2015 |
Ad = adenovirus; ConM = consensus sequence of all HIV-1 group M isolates; ConS = consensus sequence; DPBS = Dulbecco phosphate-buffered saline; eOD = engineered outer domain; gp = glycoprotein; MVA = modified vaccinia Ankara; UFO = uncleaved prefusion-optimized; VRC = Dale and Betty Bumpers Vaccine Research Center.